1. Home
  2. FLYW vs TSHA Comparison

FLYW vs TSHA Comparison

Compare FLYW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$14.39

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.49

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
TSHA
Founded
2009
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FLYW
TSHA
Price
$14.39
$5.49
Analyst Decision
Buy
Strong Buy
Analyst Count
14
8
Target Price
$16.21
$11.63
AVG Volume (30 Days)
2.1M
2.0M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
5.56
EPS
0.10
N/A
Revenue
$623,025,000.00
$9,773,000.00
Revenue This Year
$19.68
N/A
Revenue Next Year
$15.25
$1,152.42
P/E Ratio
$145.80
N/A
Revenue Growth
26.59
17.28
52 Week Low
$10.09
$2.25
52 Week High
$18.05
$7.30

Technical Indicators

Market Signals
Indicator
FLYW
TSHA
Relative Strength Index (RSI) 41.40 43.87
Support Level $12.82 $5.27
Resistance Level $15.13 $6.01
Average True Range (ATR) 0.63 0.36
MACD -0.32 -0.04
Stochastic Oscillator 16.22 36.78

Price Performance

Historical Comparison
FLYW
TSHA

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: